Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05380882
Other study ID # TQB2930-I-01
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date May 2022
Est. completion date December 2023

Study information

Verified date May 2022
Source Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact Ruihua Xu, Doctor
Phone 86-20-87343468
Email ruihxu@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

TQB2930 is an anti-HER2 (Human Epidermal Growth Factor Receptor 2) bispecific antibody that can simultaneously bind two epitopes of HER2, leading to a dual HER2 signal blockage. This is a phase I study to evaluate the safety, tolerability and effectiveness of TQB2930 injection in subjects with advanced malignancies.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 2023
Est. primary completion date April 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - 1 Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study; - 2 Male or female patient 18 to 75 years of age, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, and life expectancy =12 weeks; - 3 Histologically or cytologically confirmed, locally advanced tumors, Priority will be given to subjects with HER2 positive solid tumor; - 4 Malignant tumor that failed from standard treatment or had no standard treatment; - 5 According to the RECIST 1.1 standard, patient with at least one evaluable lesion; - 6 The main organs function well; - 7 Male or female patient had no plans to become pregnant and voluntarily took effective contraceptive measures from agree with the study to at least 6 months after the last dose of study drug. Exclusion Criteria: - 1 Concurrent secondary malignancy. or other malignancy with no evidence of disease for more than 3 years; - 2 History of uncontrolled intercurrent illness; - 3 Major surgical procedure, radiotherapy, chemotherapy, or immunotherapy within 4 weeks prior to first dose; - 4 Patients with known symptomatic brain metastases; - 5 Receiving any other investigational agent within 4 weeks before first dose; - 6 Unstable or serious concurrent medical conditions, as assessed by the Investigators, that would substantially increase the risk-benefit ratio of participating in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
TQB2930 injection
TQB2930 is an anti-HER2 bispecific antibody.

Locations

Country Name City State
China Sun Yat-sen University Cancer Center Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose Limiting Toxicity (DLT) DLT will be defined as toxicities that meet pre-defined severity criteria(according to the NCI CTCAE v5.0 toxicity assessment criteria), and assessed as having a suspected relationship to study drug that occurred from the first dose to the end of the first treatment cycle. At the end of Cycle 1 (each cycle is 21 or 28 days)
Primary Maximum tolerated dose (MTD) MTD was defined as the highest dose at which dose-limiting toxicity (DLT) occurred in less than 33% of patients. At the end of Cycle 1 (each cycle is 21 or 28 days).
Primary Adverse events (AE) rate The occurrence and severity of all AEs From date of the first dose until the date of 28 days after last dose or new anti-tumor treatment, whichever came first.
Secondary immunogenicity Incidence of anti-drug antibody (ADA) Cycle 1 Day 1, Cycle 2 Day1, Cycle 4 Day1, Cycle 7 Day1, Cycle 12 Day1: pre-dose and end of the infusion.(each cycle is 21 or 28 days)
Secondary Pharmacokinetics: The area under the curve (AUC) The area under the curve (AUC) of serum concentration of TQB2930 Cycle1Day1, Cycle1Day8, Cycle1Day815, Cycle2 Day1, Cycle2Day8, Cycle2Day15 and Cycle3Day1: pre-dose, Cycle1Day1:at 0.5, 4, 8, 24, 48, 72, and 240 hours after infusion. Cycle2Day1:at 0.5, 4, 8, 24, 48, 72, and 240 hours after infusion.(21 or 28 days each)
Secondary Pharmacokinetics:Peak concentration (Cmax) Maximum observed concentration (Cmax) of TQB2930 Cycle1Day1, Cycle1Day8, Cycle1Day815, Cycle2 Day1, Cycle2Day8, Cycle2Day15 and Cycle3Day1: pre-dose, Cycle1Day1:at 0.5, 4, 8, 24, 48, 72, and 240 hours after infusion. Cycle2Day1:at 0.5, 4, 8, 24, 48, 72, and 240 hours after infusion.21 or 28 days each
Secondary Pharmacokinetics: T1/2 Terminal half-life (T1/2) Cycle1Day1, Cycle1Day8, Cycle1Day815, Cycle2 Day1, Cycle2Day8, Cycle2Day15 and Cycle3Day1: pre-dose, Cycle1Day1:at 0.5, 4, 8, 24, 48, 72, and 240 hours after infusion. Cycle2Day1:at 0.5, 4, 8, 24, 48, 72, and 240 hours after infusion.21 or 28 days each
Secondary Objective Response Rate (ORR) Defined as the percentage of Complete Response (CR) plus partial response (PR) assessed by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 criteria From date of the first dose until the date of first documented progression or date of death from any cause, assessed up to 100weeks
Secondary Disease control rate (DCR) Defined as the proportion of subjects with CR, PR, or SD (Stable Disease). From date of the first dose until the date of first documented progression or date of death from any cause, assessed up to 100weeks
Secondary Duration of Response (DOR) Defined as the time from first documented response to documented disease progression. From date of the first dose until the date of first documented progression or date of death from any cause, assessed up to 100weeks
Secondary Progression-free survival (PFS) Defined as the time from the first dose of TQB2928 to the first occurrence of disease progression or death from any cause. From date of the first dose until the date of first documented progression or date of death from any cause, assessed up to 100weeks
Secondary Overall survival(OS) Overall survival refers to the time from the first treatment to death from any cause. From date of the first dose until the date of first documented progression or date of death from any cause, assessed up to 100weeks
See also
  Status Clinical Trial Phase
Completed NCT01213238 - Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab Phase 1
Recruiting NCT02160366 - Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer Patients
Completed NCT00903708 - LY2275796 in Advanced Cancer Phase 1
Completed NCT00379353 - The Effects of Thalidomide on Symptom Clusters Phase 2
Terminated NCT00499382 - Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging N/A
Completed NCT02459964 - Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain Phase 4
Completed NCT01430572 - Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients Phase 1
Completed NCT02561234 - A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT01375114 - The Effects of Ginseng on Cancer-Related Fatigue Phase 2
Completed NCT01201694 - Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L) Phase 1
Completed NCT01454804 - Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors Phase 1
Completed NCT02801045 - Art Therapy in Palliative Care: Study of Identification and Understanding of the Mechanisms of Change in the Patient N/A
Completed NCT02873975 - A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency Phase 2
Completed NCT01983969 - Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma Phase 1/Phase 2
Completed NCT02272595 - Rational Therapeutics Based on Matched Tumor and Normal Tissue
Active, not recruiting NCT01999491 - A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma Phase 1
Recruiting NCT03375983 - Plasmodium Immunotherapy for Advanced Cancers Phase 1/Phase 2
Completed NCT02571036 - A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies Phase 1
Withdrawn NCT01608139 - Study of Curcumin, Vorinostat, and Sorafenib Phase 1
Completed NCT01024166 - Patient-Reported Outcomes-Based Palliative and Hospice Care Practice: A Usability Study N/A